Biblio
Stem cell mutations can be detected in myeloma patients years before onset of secondary leukemias. Blood Adv. 2019;3(23):3962-3967.
Characterization of the molecular mechanism of the bone-anabolic activity of carfilzomib in multiple myeloma. PLoS One. 2013;8(9):e74191.